Statement from Dr. Carol Nacy, CEO of Sequella, Regarding World TB Day (March 24, 2013)
Maxwell Biotech Venture Fund’s Portfolio Company, Infectex, Enrolls First Multi-Drug Resistant Tuberculosis (MDR-TB) Patients in Pivotal Clinical Trial of SQ109, Licensed from Sequella
LabCorp Enters Into License Agreement with Sequella for use of B-SMART™ Technology to develop Rapid Tuberculosis Antimicrobial Susceptibility Test
Maxwell Biotech Venture Fund's Portfolio Company, Infectex, Receives Russian Regulator's Approval to Conduct Pivotal Clinical Trial for Sequella's Antibiotic, SQ109, for Tuberculosis
Sequella Licenses Rights to Commercialize SQ109 for Tuberculosis in Russia and Commonwealth of Independent States
Welcome to Sequella
Sequella is a clinical stage antiinfectives company focused on discovering, developing, and commercializing improved treatments for serious infectious diseases. The company leverages its global influence, R&D platforms and infectious disease expertise to proactively address emerging health threats. Through focused execution, clear commercialization pathways, and strategic partnerships with global pharmaceuticals and NGO's, Sequella is working to commercialize a broad product portfolio designed to treat infectious disease threats with significant market opportunity.
Sequella's growth strategy leverages a strong management team and core competencies in chemistry, microbiology, molecular biology, infectious diseases, and product development. The company's product portfolio addresses disease areas of known or suspected infectious etiology:
Mycobacterium tuberculosis infections including drug-suceptible TB, multi drug-resistant TB (MDR-TB), and extremely drug-resistant TB (XDR-TB) indications (SQ109, SQ609, Biological System for Molecular Antibiotic Resistance Testing (known as B-SMART™).
Helicobacter pylori infections (SQ109)
Gastric and duodenal ulcers, and gastric cancer indications
Clostridium difficile infections (SQ641)
M. avium paratuberculosis and other nontuberculous mycobacterial infections (SQ641)
Crohn's Disease and Buruli ulcer indications